Fintel studies that on May 25, 2023, EF Hutton reiterated protection of Aravive (NASDAQ:ARAV) with a Buy suggestion.
Analyst Price Forecast Suggests 802.04% Upside
As of May 11, 2023, the typical one-year price target for Aravive is 13.26. The forecasts vary from a low of 10.10 to a excessive of $18.90. The common worth goal represents a rise of 802.04% from its newest reported closing worth of 1.47.
See our leaderboard of companies with the biggest worth goal upside.
The projected annual income for Aravive is 1MM, a lower of 85.56%. The projected annual non-GAAP EPS is -1.37.
What is the Fund Sentiment?
There are 59 funds or institutions reporting positions in Aravive. This is a rise of 5 proprietor(s) or 9.26% within the final quarter. Average portfolio weight of all funds devoted to ARAV is 0.04%, a rise of 258.00%. Total shares owned by establishments elevated within the final three months by 22.48% to 18,695K shares. The put/call ratio of ARAV is 1.89, indicating a bearish outlook.
What are Other Shareholders Doing?
Bvf holds 4,784K shares representing 7.99% possession of the corporate. No change within the final quarter.
Artal Group holds 4,573K shares representing 7.64% possession of the corporate. No change within the final quarter.
Baker Bros. Advisors holds 3,261K shares representing 5.45% possession of the corporate. No change within the final quarter.
New Leaf Venture Partners, L.L.C. holds 946K shares representing 1.58% possession of the corporate. No change within the final quarter.
Millennium Management holds 369K shares representing 0.62% possession of the corporate. In it is prior submitting, the agency reported proudly owning 67K shares, representing a rise of 81.83%. The agency elevated its portfolio allocation in ARAV by 759.42% over the past quarter.
Aravive Background Information
(This description is supplied by the corporate.)
Aravive, Inc. is a clinical-stage oncology firm creating transformative therapeutics designed to halt the development of life-threatening illnesses. Aravive relies in Houston, Texas and obtained a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Aravive’s lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway related to tumor cell development. Aravive efficiently accomplished a Phase 1b trial of AVB-500 in platinum resistant ovarian most cancers and has initiated a registrational Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant ovarian most cancers was a security trial and never powered to display efficacy, all 5 sufferers within the 15 mg/kg cohort skilled medical profit, with 1 full response, 2 partial responses, and a pair of secure illness. The Company is dosing sufferers in its Phase 1b/2 trial in clear cell renal cell carcinoma.
Key filings for this firm:
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.